These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 34531065)

  • 1. Bexarotene: A Case Study of Medicare Part D's Specialty Drug Shortcomings.
    Puri P; Rajkumar SV; Shah ND; Pittelkow MR; Mangold AR
    Mayo Clin Proc; 2021 Oct; 96(10):2519-2522. PubMed ID: 34531065
    [No Abstract]   [Full Text] [Related]  

  • 2. Part D's underuse of generics wastes $1B per year.
    Manag Care; 2013 Jul; 22(7):68. PubMed ID: 23940871
    [No Abstract]   [Full Text] [Related]  

  • 3. Broken Promises - How Medicare Part D Has Failed to Deliver Savings to Older Adults.
    Dusetzina SB; Muluneh B; Keating NL; Huskamp HA
    N Engl J Med; 2020 Dec; 383(24):2299-2301. PubMed ID: 33283988
    [No Abstract]   [Full Text] [Related]  

  • 4. Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.
    Egilman AC; Wallach JD; Ross JS; Dhruva SS
    JAMA Intern Med; 2018 Apr; 178(4):567-569. PubMed ID: 29340562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.
    Dusetzina SB; Huskamp HA; Keating NL
    JAMA; 2019 May; 321(20):2025-2027. PubMed ID: 31135837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare Part D payments for brand and generic drugs prescribed by dermatologists.
    Powell HB; Adamson AS
    J Am Acad Dermatol; 2018 Sep; 79(3):575-577. PubMed ID: 29477736
    [No Abstract]   [Full Text] [Related]  

  • 7. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A few specialty drug prices fall--all generics.
    Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
    [No Abstract]   [Full Text] [Related]  

  • 9. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
    Socal MP; Bai G; Anderson GF
    JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
    Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
    JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug cost-sharing amounts stable 2010-2011.
    Manag Care; 2012 Jan; 21(1):59. PubMed ID: 22334940
    [No Abstract]   [Full Text] [Related]  

  • 12. Medicare part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance.
    Polinski JM; Brookhart MA; Glynn RJ; Schneeweiss S
    J Clin Psychopharmacol; 2012 Feb; 32(1):3-10. PubMed ID: 22198455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Medicare Part D Savings on Ophthalmic Generic Drugs.
    Collet DA; Urban MB; Amin A
    JAMA Ophthalmol; 2024 Jul; 142(7):678-680. PubMed ID: 38814578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
    Egilman AC; Kesselheim AS; Sarpatwari A; Rome BN
    Ann Intern Med; 2024 Jun; 177(6):833-835. PubMed ID: 38684101
    [No Abstract]   [Full Text] [Related]  

  • 15. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
    Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialty pharmacy management will become more intense.
    Collins S
    Manag Care; 2010 Oct; 19(10):20-3. PubMed ID: 21049783
    [No Abstract]   [Full Text] [Related]  

  • 17. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
    Duggan M; Morton FS
    Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
    [No Abstract]   [Full Text] [Related]  

  • 18. Changing Medicare's Protected Classes: History, Mistrust, and Budgets in the Prescription Drug Market.
    Frank RG
    Psychiatr Serv; 2019 Oct; 70(10):858-859. PubMed ID: 31480929
    [No Abstract]   [Full Text] [Related]  

  • 19. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis.
    Hohmann N; Hansen R; Garza KB; Harris I; Kiptanui Z; Qian J
    Value Health; 2018 Oct; 21(10):1186-1191. PubMed ID: 30314619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.